Infections in patients undergoing peritoneal dialysis

Infectious Disease Clinics of North America

Volumn 15, Issue 3, 2001, Pages 743-774

  Vas, Stephen ^b   Oreopoulos, Dimitrios G ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; CATHETER; HEALTH CARE COST; HUMAN; IMMUNITY; INFECTION RATE; INFECTION RISK; PATIENT SELECTION; PERITONEAL DIALYSIS; PERITONITIS; REVIEW;

EID: 0034844080     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70171-9     Document Type: Article

References (214)

1. Antibiotic lavage for peritonitis
2. Acinetobacter calcoaceticus outbreak associated with peritoneal dialysis
3. Peritonitis in patients on automated peritoneal dialysis
4. Improved detection of bacterial growth in continuous ambulatory peritoneal dialysis effluent by use of BacT/Alert FAN bottles
5. Host defense in continuous ambulatory peritoneal dialysis: The effect of dialysate on phagocyte function
6. Uncommon causes of peritonitis in patients undergoing peritoneal dialysis
7. Effect of the Peridex filter on peritonitis rates in a CAPD population
8. Comparison of microbiologic characteristics of pathogenic and saprophytic coagulase negative staphylococci from patients on continuous ambulatory peritoneal dialysis
9. Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis
10. Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored?
11. Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy
12. Single or multiple daily doses of aminoglycosides. A meta-analysis
13. Peritonitis due to a Mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis
14. Candida peritonitis
15. Continuous ambulatory peritoneal dialysis and acute appendicitis
16. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin
17. Limulus amoebocyte lysate assay in the diagnosis of peritonitis in patients receiving continuous ambulatory peritoneal dialysis
18. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis: A prospective randomized comparision of intermittent vs continuous therapy
19. Recurrent CAPD peritonitis caused by coagulase-negative staphylococci: Reinfection or relapse determined by clinical criteria and typing methods
20. A unifying pathogenetic mechanism in the etiology of intraperitoneal adhesions
21. Culture methods for continuous ambulatory peritoneal dialysis associated peritonitis
22. Culture-negative CAPD peritonitis: The network 9 study
23. Pharmacokinetics of common antibiotics used in continuous ambulatory peritoneal dialysis
24. Randomized trials of aminoglycoside antibiotics: Quantitative overview
25. Clinical aspects of bowel perforation in patients undergoing continous ambulatory peritoneal dialysis
26. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): A multicenter randomized clinical trial comparing the Y connector disinfectant system to standard systems
27. An electron microscopical study of the passage of ions through the endothelium of lymphatic and blood capillaries, and through the mesothelium
28. Pseudomonas peritonitis in CAPD patients: Characteristics and outcome of treatment
29. Ketoconazole and fungal CAPD peritonitis
30. Fungal peritonitis complicating peritoneal dialysis: Report of 27 cases and review of treatment
31. Vestibular toxicity due to gentamicin in peritoneal dialysis patients
32. Adherence of slime producing strains of Staphylococcus epidermidis to smooth surfaces
33. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): A multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems
34. Peritonitis in CAPD patients - A randomized clinical trial of trimethoprim-sulfamethoxazole prophylaxis
35. Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis
36. Prolonged peritoneal dialysis in patients awaiting renal transplantation
37. The effect of intranasal mupirocin on CAPD exit site infection (ESI)
38. CAPD and cellular immunity: No different than hemodialysis patients
39. Recurrent peritonitis associated with vaginal leak
40. Infective endocarditis and access site infections in patients on hemodialysis
41. Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis
42. Bacteriological and clinical evaluation of different dialysate delivery systems
43. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in continuous ambulatory peritoneal dialysis
44. Continuous cyclic peritoneal dialysis: The Nalle Clinic experience
45. Peritoneovaginal fistula - Unusual complication of peritoneal dialysis
46. Morbidity and mortality after treatment of peritonitis with prolonged exchanges and intraperitoneal antibiotics
47. Tuberculous peritonitis: 43 Years experience in diagnosis and treatment
48. Intermittent intraperitoneal ceftazidime dosing in end-stage renal disease
49. Effect of composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro
50. The etiology of post-operative abdominal adhesions. An experimental study
51. The cause and prevention of post-operative intraperitoneal adhesions
52. Laboratory diagnosis in patients undergoing continuous ambulatory peritoneal dialysis
53. The treatment of acute renal failure by peritoneal irrigation
54. Continuous ambulatory peritoneal dialysis catheter infections: Diagnosis and management
55. Further experiences with peritoneal irrigation for acute renal failure
56. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients
57. Serosal hypofibrinolysis. A cause of post-operative adhesions
58. The influence of peritoneal dialysis on cellular immunity
59. Once-daily aminoglycoside therapy
60. Changes in some inflammatory proteins during peritonitis in CAPD patients
61. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 Update. (Official report from the International Society for Peritoneal Dialysis)
62. Risk of tobramycin use in CAPD patients with peritonitis
63. Nasal and cutaneous Staphylococcus among patients receiving hemodialysis and attending personnel
64. Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients
65. Fibronectin and complement secretion by monocytes and peritoneal macrophages in vitro from patients undergoing continuous ambulatory peritoneal dialysis
66. Factors affecting development of peritonitis in continuous ambulatory peritoneal dialysis
67. Aminoglycoside-induced ototoxicity
68. Pharmacokinetics of intermittent intraperitoneal ceftazidime
69. Toxic shock following staphylococcal peritonitis
70. Species identification and antibiotic sensitivity of coagulase negative staphylococci from CAPD peritonitis
71. Peritonitis associated with exit site and tunnel infections
72. Failure to cure Mycobacterium gordonae peritonitis associated with continuous ambulatory peritoneal dialysis
73. Effect of dialysate fluids on phagocytosis and killing by normal neutrophils
74. Secondary bacterial peritonitis. The biologic basis of treatment
75. Fibrinolytic activity of the peritoneum during experimental peritonitis
76. Shaving of external cuff or peritoneal catheter
77. Management of Candida peritonitis by prolonged peritoneal lavage containing 5-fluorocytosine
78. A prospective evaluation of blood culture versus standard plate techniques for diagnosing peritonitis in continous ambulatory peritoneal dialysis
79. Biofilm and foreign body infection - The significance to CAPD associated peritonitis
80. Plasmid profile and slime analysis of coagulase negative staphylococci from CAPD patients with peritonitis
81. Clinical features of and risk factors for fungal peritonitis in peritoneal dialysis patients
82. The neutrophil function of uremic patients treated by hemodialysis or CAPD
83. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: A double blind trial
84. Formation of intraperitoneal abscesses by Staphylococcus aureus
85. Epidemic of aseptic peritonitis caused by endotoxin during chronic peritoneal dialysis
86. Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment
87. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 Update
88. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis
89. Fibronectin in the normal peritoneal fluids of patients on chronic ambulatory peritoneal dialysis and during peritonitis
90. Fungal peritonitis in patients undergoing chronic intermittent or continuous peritoneal dialysis
91. Treating fungal infections: Fungal peritonitis in CAPD
92. Laboratory diagnosis and oral treatment of CAPD patients
93. Impaired initial cell reaction in CAPD-related peritonitis
94. Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution
95. CAPD peritonitis - Initial presentation as an acute abdomen with a clear peritoneal effluent
96. Defective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): Importance and prevention
97. Suppressor resident peritoneal macrophages and peritonitis incidence in continuous ambulatory peritoneal dialysis
98. Mycobacterium fortuitum peritonitis in a patient undergoing chronic peritoneal dialysis
99. Flucytosine miconazole treatment of Candida peritonitis: Its use during continuous ambulatory peritoneal dialysis
100. New dosing regimens for aminoglycoside antibiotics
101. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Part 2
102. Host defense mechanisms in the peritoneal cavitiy of continuous ambulatory peritoneal dialysis patients. Part 1
103. Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter
104. The bacteriology of intra-abdominal infections
105. Pharmacokinetics of once-daily ip gentamicin in CAPD patients
106. Randomized clinical trial of prophylactic cephalexin in CAPD
107. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis
108. Exit-site care and exit-site infection in CAPD: Results of a randomized multicenter trial
109. Once-daily intraperitoneal gentamicin is effective therapy for gram-negative CAPD peritonitis
110. On the mechanism of absorption of granular materials from the peritoneum
111. Peritonitis during peritoneal dialysis. The role of the preheating water bath
112. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients
113. Drugs and peritoneal dialysis
114. Examination of the morphology of bacteria adhering to peritoneal dialysis catheters by scanning and transmission electron microscopy
115. Fusarium peritonitis: An uncommon complication
116. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis
117. Analysis of factors responsible for the formation of adhesions during chronic peritoneal dialysis
118. Renal failure and infection
119. High index of suspicion for tuberculous peritonitis in CAPD patients
120. Fibrinolytic activity in serosal and synovial membrane
121. A technique for managing exit site and cuff infection in Tenckhoff catheters
122. Is intraperitoneal tobramycin ototoxic in CAPD patients?
123. Tuberculous peritonitis in patients on CAPD: The importance of lymphocytosis in the peritoneal fluid
124. The effects of a minidose of heparin on peritonitis in rats
125. Microbial synergy in experimental intra-abdominal abscess
126. A simple and safe technique for continuous ambulatory peritoneal dialysis (CAPD)
127. Prevention of peritonitis during continuous ambulatory peritoneal dialysis
128. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis
129. Prolonged peritoneal dialysis for chronic renal failure
130. Removal and replacement of Tenckhoff catheter at a single operation: Successful treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis
131. Penicillium peritonitis in a CAPD patient
132. Adherence and growth of coagulase negative staphylococci on surfaces of intravenous catheters
133. Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages
134. Group JK Corynebacterium peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis
135. Failure of peritoneal cuff shaving to eradicate infection
136. Chemical peritonitis due to intraperitoneal vancomycin (Vancoled)
137. The influence of peritoneal catheter exit site infections on peritonitis, tunnel infections and catheter loss in patients on continuous ambulatory peritoneal dialysis
138. Mycobacterium chelonei peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD)
139. The definition of a novel portable/wearable equilibrium peritoneal dialysis technique
140. Continuous ambulatory peritoneal dialysis
141. The definition of a novel portable/wearable equilibrium peritoneal dialysis technique
142. Fibrinolytic activity of mesothelial surfaces
143. Peritoneal dialysis exit site care: Results of an international survey
144. Inoculation of peritoneal dialysate fluid into blood culture bottles improves culture rates
145. Antibiotic activity in peritoneal dialysate
146. Host defense mechanisms in continuous ambulatory peritoneal dialysis
147. Management of peritonitis and bowel perforation during chronic peritoneal dialysis
148. Peritonitis during continuous ambulatory dialysis
149. Continuous ambulatory peritoneal dialysis: Dialysate fluid cultures
150. Post-operative peritoneal adhesions. A study of the mechanisms
151. Hepatitis B surface antigen (HB(s)Ag) in peritoneal fluid of HB(s)Ag carriers undergoing peritoneal dialysis
152. Ten years survey of dialysis associated tuberculosis
153. Peritoneal sclerosis. A sword of Democles for peritoneal dialysis
154. Transmural migration of intestinal bacteria. A study based on the use of radioactive Escherichia coli
155. Sclerosing peritonitis, Letters to the editor 1983
156. Treatment of experimental uremia by means of peritoneal irrigation
157. Stability of antimicrobial agents in peritoneal dialysate
158. Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin
159. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate
160. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients
161. Infections associated with subclavian Uldall catheters
162. Clostridia and antimicrobial enterocolitis
163. Perforating injuries of the bowel complicating peritoneal catheter insertion
164. Tuberculous peritonitis: An evaluation of pathogenic mechanisms, diagnostic procedures and therapeutic measures
165. Treatment of peritoneal dialysis related infections by simultaneous catheter removal and replacement. Is it safe?
166. Emergence of vancomycin resistance in Staphylococcus aureus
167. Propionibacteria isolates and asymptomatic infections of the peritoneal effluent in CAPD patients
168. Bacteremia: Laboratory and clinical aspects
169. Identification of peritoneal dialysis catheter tunnel infection by scanning with Indium-111 labelled leukocytes
170. Clinical observations on the pathogenesis of peritoneal dialysate eosinophilia
171. Peritoneal dialysis: Peritonitis: Saline iodine flush
172. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections
173. Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: Case report and review
174. Experience with maintenance peritoneal dialysis in the home
175. A bacteriologically safe peritoneal access device
176. Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis
177. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site
178. Early peritoneal catheter removal may be life saving in fungal peritonitis
179. Peritonitis during continuous ambulatory peritoneal dialysis (CAPD): Risk factors, clinical severity, and pathogenetic aspects
180. Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis
181. Persistence of positive dialysate cultures after apparent cure of CAPD peritonitis
182. Peritonitis associated with intra-abdominal pathology in continous ambulatory peritoneal dialysis patients
183. The need for a center-tailored treatment protocol for peritonitis
184. Peritonitis of peritoneal dialysis patients: Pathogenesis and treatment
185. Microbiologic aspects of chronic ambulatory peritoneal dialysis
186. Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics
187. Indications for removal of peritoneal catheter
188. The need for antibiotic prophylaxis during peritoneal dialysis
189. Handle with care: Hepatitis B antigen carriers in peritoneal dialysis units
190. Microbiological diagnostic approach to peritonitis in CAPD patients
191. Renaissance of tuberculosis in the 1990s: Lesson for the nephrologist
192. Vaccination for peritoneal dialysis patients
193. Microbiological diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis
194. Peritoneal macrophages and opsonins: Antibacterial defense in patients undergoing chronic peritoneal dialysis
195. Biofilm on Tenckhoff catheters: A negligible source of contamination
196. Lymphoma-mimicking peritonitis in a patient on continuous ambulatory peritoneal dialysis (CAPD)
197. Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis
198. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients
199. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis
200. Nontuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patients
201. Phagocytosis and neutrophil bactericidal capacity in patients with uremia
202. The value of dialysate cell count in the diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis
203. Tobramycin blood levels of CAPD patients during peritonitis
204. Routine daily surveillance cultures in the management of CAPD patients
205. Tenckhoff catheter replacement or intraperitoneal urokinase: A randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis
206. Treatment of peritonitis in patients on CAPD: To lavage or not
207. Tuberculous peritonitis and role of diagnostic laparoscopy
208. Review of peritonitis episodes that caused interruption of CAPD
209. Is extensive diverticulosis of the colon a contraindication to CAPD
210. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: Efficacy of antibiotic prophylaxis
211. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis related infections